Long term reference change value of creatinine in HIV-positive patients with anti-retroviral therapy: A new tool in clinical practice

Stéfanie Badiou, A. Cournil, Anne-Sophie Bargnoux, S. Toubal, A.M. Dupuy, C. Fernandez, H. Peyriere, J. Reynes, Jean-Paul Cristol

To cite this version:

HAL Id: hal-01767864
https://hal.umontpellier.fr/hal-01767864
Submitted on 21 Jul 2018
Long term reference change value of creatinine in HIV-positive patients with anti-retroviral therapy: A new tool in clinical practice

S. Badiou a,b, A. Cournil c, S. Toubaï a, A.S. Bargnoux a, A.M. Dupuy a, C. Fernandez d, H. Peyriere c, J. Reyes c,d, J.P. Cristol a,b,⁎

a Department of Biochemistry, Montpellier University Hospital, Montpellier, France
b UMR 204 NUTRIPASS, Université Montpellier UII, Montpellier, France
c UMR 233, IRD Inst Res Dev, Université Montpellier I, Montpellier, France
d Department of Infectious Diseases, Montpellier University Hospital, Montpellier, France

A B S T R A C T

Background: The use of reference change value (RCV) instead of reference interval emerged as an alternative approach for longitudinal interpretation of biological marker. Follow-up of creatinine variation in HIV-positive adults remains a challenge in order to prevent renal complications.

Objectives: To determine the long term RCV of creatinine in HIV-positive adults receiving anti-retroviral therapy (ART) according to the use of tenofovir or ritonavir.

Design and methods: Longitudinal study of 24 months that include 124 HIV-positive patients followed in HIV outpatient unit. Plasma creatinine was measured at 0, 6, 12 and 24 months in order to calculate the RCV.

Results: In the whole group, a 24-month RCV of creatinine was 22.5%. Whatever the ART, the index of individuality was <0.6. Significantly higher RCV of creatinine was observed in patients receiving the association tenofovir and ritonavir (28%) compared to the patients receiving i) tenofovir without ritonavir (21.9%), ii) no tenofovir but ritonavir (22.2%), and iii) no tenofovir and no ritonavir (19.7%).

Conclusions: The low value of index of individuality pinpointed that RCV should be used to identify critical change in serial creatinine results in HIV-positive adults. RCV of creatinine under ART was around 20% but reached 28% in case of association of tenofovir and ritonavir.

Keywords:
Creatinine, HIV, Ritonavir, Reference change value, Renal, tenofovir

Introduction

Plasma creatinine level is commonly used as a biomarker for renal function assessment. Single level of plasma creatinine is mainly interpreted using reference interval values or integrated in algorithms in order to estimate the glomerular filtration rate (GFR) [1]. Reference interval values for creatinine are variable for age and gender, often provided by manufacturers, but should be re-assessed in each laboratory for each method in healthy volunteers. Nevertheless, serial measures of plasma creatinine level could be interpreted through another approach using the reference change value (RCV) instead of reference interval. The concept of RCV takes into account the analytical and biological variations of a biomarker in order to determine which percent change between two consecutive measurements may be considered as a critical difference [2]. Biological variations depended to intra- and inter-individual variations, assessed through within-(CVi) and between-(CVg) subject coefficients of variation, respectively.

⁎ Corresponding author at: Department of Biochemistry, Lapeyronie Hospital, F34295 Montpellier, France.
E-mail address: jp-cristol@chu-montpellier.fr (J.P. Cristol).

Determination of RCV for a biomarker in a healthy population is not always transposable to specific clinical conditions [3], as demonstrated recently for renal recipient patients [4]. No data are available today, for RCV of creatinine in HIV-positive patients. The purpose of the present study was to calculate long term RCV of creatinine in HIV-positive adults receiving anti-retroviral therapy (ART).

Patients and methods

This is a longitudinal study of HIV-positive adults seen at the Montpellier University Hospital HIV outpatient clinic. The study was approved by the local ethic committee and was declared under the number DC-2012-1579. All patients enrolled have serial monitoring at 0, 6 (±1), 12 (±1) and 24 (±1) months in the department of Infectious Diseases, with a standardized biological assessment including creatinine measure with enzymatic method (DiaSys reagent, DiaSys Diagnostic System, Holzheim, Germany) adapted on AU2700 Olympus analyzer (Beckman, Villepinte, France). Clinical and biological data were included in a computerized medical record (e-NADIS), after patients received oral information and given written consent. Patients were included if they are clinically stable, without change of ART, with an estimated
GFR (eGFR) > 60 ml/min/1.73 m² during the study period. The eGFR was determined using the CKD-EPI formula [1]. Patients with creatinine levels higher than 110 μmol/l for male or 90 μmol/l for women were excluded. Patients were divided in four groups according to their ART: group T+/−: receiving tenofovir, no ritonavir; group T+/+: receiving tenofovir and ritonavir; group T−/−: receiving no tenofovir, no ritonavir; and group T−/+: receiving ritonavir, no tenofovir. RCV was calculated using the formula RCV = CV² + CV²)1/2, with a Z score = 1.96 for p < 0.05 [2]. Analytical coefficient of variation (CVa) was determined in accordance with the CLSI EP15 protocol [5]. A total CV (CVt) was calculated for each patient using the results of his four serial measures (0–6–12–24 months). The CVt was obtained after removing the analytical variation with the formula CVt = (CV² + CV²)1/2. The index of individuality (II) was assessed through the ratio CVi/CVg, with CVg calculated as between-subjects variation.

**Results**

The study group consisted of 124 HIV-positive ART experienced, mean of age 50 ± 10 years. 72% were male, 14.3% had hepatitis C co-infection (anti-HCV +): 7.1% arterial hypertension and 4.0% diabetes. Median [min–max] CD4 was 526 [141–1228] cells/mm, 83% had undetectable viral load, 23.8% had AIDS stage. For all patients median [min–max] of creatinine during the study period was 73 [42–110] μmol/l, while median [min–max] of eGFR was 100 [62–151] ml/min/1.73 m². Levels of creatinine and eGFR according to the ART group are presented in Table 1. Cva for creatinine measurement using a pool of plasma at 60 μmol/l was determined as 2.8%. Results for calculation of RCV, CVi, CVg, and II are presented in Table 2, for all patients and for groups according to the ART. A significant difference was observed between RCV calculated in patients receiving the association tenofovir and ritonavir compared to each other group (p < 0.05). By contrast there is no difference of creatinine RCV between groups receiving no ritonavir or with/without tenofovir (21.9% vs 19.7%). All groups exhibited an II <0.6, although patients of the group T+/+ have a different profile than the three others, with higher value of the index of individuality.

**Discussion**

This study determined for the first time the long term RCV of creatinine in HIV-positive adults, according to their ART. This approach would be of particular interest in these patients who are monitored longitudinally in order to identify a critical change in creatinine results. Our data evidenced higher biological variations in patients receiving the association of tenofovir and ritonavir compared to the three other groups. In this study, Cva was acceptable in regard to the value of Cvi, as opposed such as ritonavir and cobicistat. Indeed, RCV in this group was 28% compared to 21.9% for tenofovir without ritonavir (p = 0.001, Student’s T-test) and to 22.2% for ritonavir without tenofovir (p < 0.05, Student’s T-test). It could be hypothesized that the association of tenofovir and ritonavir leads to high variability of creatinine. In HIV-ART experienced patients, several factors could affect creatinine levels. Difficulty remains to identify the part of creatinine variations due to an alteration of muscular mass, of glomerular function or of tubular secretion. Indeed beyond glomerular filtration, a part of creatinine is uptaken through basolateral transporters of proximal tubular cells and thereafter extruded at the apical membrane. In vitro studies, identified the organic cation transporter (OCT)-2 as main basolateral transporter of creatinine in human kidney cells [9]. More recently, using transfected cells, OAT-2 and OCT-3 were also identified in addition to OCT-2 as basolateral transporters of creatinine [10]. So, competitors for OCT transporters, such as antibiotic ( fluoroquinolone) [11] or antiretroviral drug (dolutegravir) [12], lead to decreased uptake of creatinine and consequently mild increase of plasma creatinine levels. At the apical membranes of tubular cells, extrusion of creatinine involves human multidrug and toxin extrusion (MATE)-1 and -2 [13,14]. Some inhibitors of MATE-1 including cinetidine or antiretroviral drugs such as ritonavir and cobicistat could also decrease tubular secretion of creatinine [10]. By contrast tenofovir had only a weak inhibitory effect on MATE-1 [15]. However, it could be hypothesized that a synergistic effect of ritonavir and tenofovir occurred for inhibition of MATE-1, according to the higher RCV observed in patients receiving the association of both drugs.

**Conclusions**

The present study underlined the need to use RCV instead of interval reference for creatinine in HIV-positive patients receiving ART due to the low value of the index of individuality. Because a significant difference in RCV was observed between groups, determination of RCV according to the ART is of particular interest. This study highlighted that RCV of creatinine during ART was around 20% but could be higher using the association of tenofovir and ritonavir. So, RCV of creatinine should be established for all line of treatments, especially for association of antiretroviral drugs interacting with tubular transporter of creatinine such as ritonavir and cobicistat.

---

**Table 1**

<table>
<thead>
<tr>
<th>Creatinine (μmol/L)</th>
<th>eGFR (ml/min/1.73 m²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>T+/− (n = 24)</td>
<td>73 [48–105]</td>
</tr>
<tr>
<td>T+/+ (n = 24)</td>
<td>77 [50–110]</td>
</tr>
<tr>
<td>T−/− (n = 38)</td>
<td>72 [42–103]</td>
</tr>
<tr>
<td>T−/+ (n = 38)</td>
<td>74 [43–110]</td>
</tr>
</tbody>
</table>

**Table 2**

<table>
<thead>
<tr>
<th>CVg</th>
<th>CVi</th>
<th>II</th>
<th>RCV</th>
</tr>
</thead>
<tbody>
<tr>
<td>n (%)</td>
<td>Mean (%)</td>
<td>Mean (%)</td>
<td>Mean (%)</td>
</tr>
<tr>
<td></td>
<td>[95% CI]</td>
<td>[95% CI]</td>
<td>[95% CI]</td>
</tr>
<tr>
<td>All patients</td>
<td>124</td>
<td>19.2</td>
<td>7.4</td>
</tr>
<tr>
<td>T+/−</td>
<td>24</td>
<td>20.9</td>
<td>7.2</td>
</tr>
<tr>
<td>T+/+</td>
<td>24</td>
<td>16.8</td>
<td>5.6–8.8</td>
</tr>
<tr>
<td>T−/−</td>
<td>38</td>
<td>216.5</td>
<td>6.4</td>
</tr>
<tr>
<td>T−/+</td>
<td>38</td>
<td>20.8</td>
<td>5.4–7.4</td>
</tr>
</tbody>
</table>

*p = 0.05, **p < 0.001 compared to T+/− (Student’s T-test). p = 0.05, ***p < 0.001 compared to T+/+ (Student’s T-test). $p = 0.001 compared to T−/+ (Student’s T-test).
Conflict of interest and source of funding for this work

None for any authors.

References


